Author argues ICRL is deeply undervalued at 8.7x EV/EBITDA versus industry acquisition multiples of 12.5-14x, with a temporary accounting concern that should resolve, expecting a 3x return in 18 months.
ICRL — LONG The author claims ICRL trades at 8.7x EV/EBITDA, far below the 12.5-14x multiples seen in industry acquisitions and Medpace's 20x, making it deeply undervalued. The stock dropped on an accounting controls warning involving a potential 2% timing difference in revenues over two prior years, which the author views as a minor issue given 20%+ margins and complex multi-year contracts. Similar controls issues at Syneos resolved and the stock bounced back, so the author expects ICRL to at least 3x within 18 months once the dust settles.
ICRL is on sale today. 8.7 ev/ebitda. Lowest multiple for industry acquisition of even small cos has been 12.5 to 14 times.
This Reddit post, published February 12, 2026, features u/Assume-Ass-U-Me discussing ICLR. 1 trade idea extracted by AI with direction and confidence scoring.
Speakers: u/Assume-Ass-U-Me · Tickers: ICLR